All In MedTech

Device Trial Radar · NCT02539095

Efficacy of Intra-articular Collagen Injection in Patients With Knee Joint Pain Compared to Normal Saline Injection

Intra-articular Injection of Type I Atelocollagen to Alleviate Knee Pain: A Double-blind, Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

Apr 2014

Primary completion

Aug 2015

Study completion Aug 2015

Sponsor

Lead sponsor
Cellontech Co., Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Sep 2, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 19 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to confirm the superiority of intra-articular collagen injection in patients with knee joint pain compared to the control group. 100mm VAS is used to measure the pain of the subjects 24 weeks after the procedure.

Conditions

  • Chondromalacia
  • Osteoarthritis
  • Traumatic Arthritis

Interventions

  • CartiZolDevice

    The product, CartiZol, which contains absorbable collagen, is applied on the cartilage defect to stimulate the neovasculization and cell penetration and to assist the natural wound healing process. It supplements the defective or damaged cartilage. Place the needle on the tip of the syringe and inject the product into the articular cavity.

  • Normal salineDrug

    1. Supplementation of fluid and electrolytes (sodium or chlorine deficiency) 2. Diluent for injection solution Place the needle on the tip of the syringe and inject the product into the articular cavity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 100 mm Visual Analogue Score (VAS)Time frame: 24 weeks after injection

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Chung-Ang University Hospital

    Seoul, South Korea

  • Kunkuk University Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.